De Novo ramp velocity.
De Novo ramp velocity.
Making new healthcare locations financially productive faster.
Every new location is a capital deployment decision.
It comes with a modeled ramp timeline, a projected break-even, and an EBITDA contribution built into your investment thesis.
When a location misses its ramp targets, the cost isn’t just underperformance – it’s a drag on portfolio IRR that compounds across every new opening.
We’ve built a launch framework designed to compress that curve, and it works across specialty types. Whether you’re opening behavioral health centers, ophthalmology clinics, urgent care sites, or any other new healthcare location in a multi-site platform, the underlying problem is the same: healthcare marketing didn’t start early enough, wasn’t localized enough, and wasn’t designed to generate real demand before the doors opened.
The real cost of a month.
The difference between a 12-month ramp and an 18-month ramp is six months of below-target EBITDA contribution.
Multiply that across 10 or 20 new openings a year, and the portfolio impact is material.
Every extra month of ramp is a direct drag on IRR. Every inconsistent launch signals to your sponsors that your growth model lacks the repeatability PE-backed platforms are valued on.
The problem rarely lives in the clinical operation or the new location itself.
It lives in a launch marketing strategy that started too late, relied too heavily on broad awareness, and didn’t generate enough qualified demand in the immediate trade area before opening day.
Our De Novo launch framework.
We start 90 days before the first appointment. That lead time isn’t a preference – it’s what the data shows is required to build sufficient local awareness and generate a meaningful demand pipeline before the location opens.
Pre-opening local awareness campaigns
Build brand recognition in the trade area before the first appointment is scheduled
Hyper-targeted digital advertising
Reaching high-intent patients or clients in the immediate geography
First-mover digital infrastructure
Google Business Profile optimization, local SEO, and review seeding, so the location ranks and converts from day one
Weekly launch reporting
Against ramp benchmarks, so you know exactly how each new location is tracking against thesis
Conversion-optimized landing pages
Call tracking and offer sequencing designed to turn awareness into scheduled appointments
We treat De Novo launch strategy as a capital efficiency problem, not a marketing event.
Predictability is the product.
What sponsors want from new location growth isn’t just success. It’s repeatability.
Inconsistent De Novo performance erodes sponsor confidence faster than almost anything else. Our goal is to eliminate that variability by standardizing launch performance across every market you enter.
The result: a ramp curve that tracks to or beats your investment thesis, a more efficient use of launch capital, and a playbook that scales as the portfolio grows.
You shouldn’t be spending month six trying to recover from a soft opening. With the right pre-launch infrastructure, you won’t be.
The question your operating partner is already asking.
How often are you hitting your modeled ramp timelines?
We measure success the same way you do: revenue per active patient or client, share of wallet per patient, same-site EBITDA contribution, and capacity utilization. When these metrics move, the impact is visible in your operating results – not buried in a campaign dashboard.
If the honest answer is ‘sometimes’ or ‘it depends on the market,’ that’s not a market problem. It’s a healthcare marketing infrastructure problem, and it’s fixable.
A DSO with over 160 locations used our De Novo launch framework across their network – starting earlier, going deeper on local market activation, and building the demand pipeline before the doors opened.
Book a 30-minute De Novo ramp diagnostic.
We’ll assess your current launch infrastructure, benchmark it against ramp performance norms, and identify the specific gaps creating drag on your IRR.
Thirty minutes. Specific findings. No sales pitch.
